Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AB801 in Healthy Volunteers
NCT06004921Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Oct 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AB801 in solid tumor and non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Arcus Biosciences. Primary endpoints: Number of Participants with Adverse Events up to 30 days, Area Under the Plasma Drug Concentration-Time Curve and 3 more. Started Oct 2023; status: completed.
02
Drugs
AB801
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06004921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004921.